United Health Services (UHS)

nyuhs.org

United Health Services (UHS) is the largest comprehensive healthcare system and leading private employer in the Greater Binghamton, N.Y., region. With more than 60 locations in Broome and surrounding counties, the system is composed of providers and supporting organizations serving the 600,000 residents of the Southern Tier of upstate New York and portions of Northeast Pennsylvania. A locally owned, 916-bed, not-for-profit system, it is governed by a Board of Directors made up of community citizens who volunteer their time. The employees, providers, volunteers and leadership of UHS share a commitment and promise to the people whom they serve: We will listen. We will show respect. We will give hope.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

SLATE BIO ANNOUNCES THE LAUNCH WITH SEED FINANCING TO DEVELOP NEXT GENERATION IL-2 THERAPIES

Slate Bio | January 20, 2021

news image

Slate Bio, Inc., reports the closing of a $1.75 million venture financing. Epidarex Capital drove the speculation round with cooperation from the UVA Licensing and Ventures Group Seed Fund, Center for Innovative Technology's GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., the board and others. Record is a pre-clinical biotechnology organization creating outlook changing IL-2 mixes dependent on examination directed at the University of Virginia School of Medicine. IL233, Slate's ...

Read More

INDUSTRIAL IMPACT, MEDICAL

HITGEN ANNOUNCES RESEARCH AGREEMENT WITH NITRASE THERAPEUTICS FOCUSED ON DNA-ENCODED LIBRARY BASED DRUG DISCOVERY

HitGen Inc. | December 12, 2022

news image

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered by Nitrase that are involved in a broad variety of diseases. Nitrases have been implicated in numerous devastating diseases, including Parkinson's, cancer, respiratory diseases, fibrosis ...

Read More

BIOCLINICA ANNOUNCES THAT IT WILL LEVERAGE BIOCLINICA'S INTERACTIVE RESPONSE TECHNOLOGY (IRT) FOR THEIR EXIT COVID-19 STUDY

Bioclinica | September 10, 2020

news image

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, announced today that Direct Biologics, a market leading innovator and science-based manufacturer of regenerative products, will leverage Bioclinica's Interactive Response Technology (IRT) for their EXIT COVID-19 study — a multi-center FDA phase II clinical trial for the use of ExoFlo&tr...

Read More

INDUSTRIAL IMPACT

ORDAŌS AND NONEXOMICS ANNOUNCE RESEARCH COLLABORATION

Ordaōs and NonExomics | September 29, 2022

news image

Ordaōs, a biotechnology company designing novel miniPROTM mini-proteins to help drug hunters deliver life-saving treatments, and NonExomics, a company specializing in the identification of novel targets from non-conventional protein-coding regions, announced a proof-of-concept research collaboration. As part of this endeavor, Ordaōs will use its proprietary design engine to generate and rank novel miniPRO™ candidates that meet specific target product profiles, beginning with three targets....

Read More
news image

MEDICAL

SLATE BIO ANNOUNCES THE LAUNCH WITH SEED FINANCING TO DEVELOP NEXT GENERATION IL-2 THERAPIES

Slate Bio | January 20, 2021

Slate Bio, Inc., reports the closing of a $1.75 million venture financing. Epidarex Capital drove the speculation round with cooperation from the UVA Licensing and Ventures Group Seed Fund, Center for Innovative Technology's GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., the board and others. Record is a pre-clinical biotechnology organization creating outlook changing IL-2 mixes dependent on examination directed at the University of Virginia School of Medicine. IL233, Slate's ...

Read More
news image

INDUSTRIAL IMPACT, MEDICAL

HITGEN ANNOUNCES RESEARCH AGREEMENT WITH NITRASE THERAPEUTICS FOCUSED ON DNA-ENCODED LIBRARY BASED DRUG DISCOVERY

HitGen Inc. | December 12, 2022

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered by Nitrase that are involved in a broad variety of diseases. Nitrases have been implicated in numerous devastating diseases, including Parkinson's, cancer, respiratory diseases, fibrosis ...

Read More
news image

BIOCLINICA ANNOUNCES THAT IT WILL LEVERAGE BIOCLINICA'S INTERACTIVE RESPONSE TECHNOLOGY (IRT) FOR THEIR EXIT COVID-19 STUDY

Bioclinica | September 10, 2020

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, announced today that Direct Biologics, a market leading innovator and science-based manufacturer of regenerative products, will leverage Bioclinica's Interactive Response Technology (IRT) for their EXIT COVID-19 study — a multi-center FDA phase II clinical trial for the use of ExoFlo&tr...

Read More
news image

INDUSTRIAL IMPACT

ORDAŌS AND NONEXOMICS ANNOUNCE RESEARCH COLLABORATION

Ordaōs and NonExomics | September 29, 2022

Ordaōs, a biotechnology company designing novel miniPROTM mini-proteins to help drug hunters deliver life-saving treatments, and NonExomics, a company specializing in the identification of novel targets from non-conventional protein-coding regions, announced a proof-of-concept research collaboration. As part of this endeavor, Ordaōs will use its proprietary design engine to generate and rank novel miniPRO™ candidates that meet specific target product profiles, beginning with three targets....

Read More